(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -9.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
C4 Therapeutics's revenue in 2025 is $30,108,000.On average, 8 Wall Street analysts forecast CCCC's revenue for 2025 to be $2,776,210,418, with the lowest CCCC revenue forecast at $2,089,474,852, and the highest CCCC revenue forecast at $3,663,365,000. On average, 8 Wall Street analysts forecast CCCC's revenue for 2026 to be $2,268,669,611, with the lowest CCCC revenue forecast at $0, and the highest CCCC revenue forecast at $4,070,405,556.
In 2027, CCCC is forecast to generate $2,268,669,611 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,561,604,862.